|
|
Details: |
|
|
Official Pharmaceutical Website with information for consumers and health professionals.
|
URL: |
http://www.donnatal.com
|
Title: |
Donnatal & Irritable Bowel Syndrome (IBS) - All Day, All Night... |
Image: |
|
Description: |
Health, Pharmacy, Drugs and Medications, B - Donnatal Extentabs - PBM Pharmaceuticals. Official Pharmaceutical Website with information for consumers and health professionals. |
Specialized in: |
Irritable Bowel Syndrome
-
Ibs
|
|
|
Related Sites |
|
Regranex (Popularity: ): Features product information and a guide to good foot care.
Avastin.com (Popularity: ): Official pharmaceutical website with information for patients and health professionals.
Pulmicort Respules (Popularity: ): Drug and asthma management resources for US health care professionals. Includes drug information, patient materials, and prescribing information.
MS Pathways (Popularity: ): From Berlex. Offers drug and disease information for US residents.
Tracleer (Popularity: ): Features an overview of pulmonary hypertension, prescribing information for US residents, and press releases.
BuSpar Anxiety Relief Center (Popularity: ): Advice for patients and health professionals, from the Bristol-Myers Squibb Company.
Pulmicort Turbuhaler (Popularity: ): Features information about how to use the drug, full prescribing information for US residents, and a glossary as well as ...
Suboxone / Subutex (Popularity: ): Information for healthcare professionals and patients.
Rebif (Popularity: ): An interferon beta 1-a for relapsing forms of MS. Find out about recommended dose, potential side effects, clinical studies and ...
Symbicort - AstraZeneca International (Popularity: ): An asthma treatment consisting of the inhaled corticosteroid budesonide together with the rapid- and long-acting ß2-agonist formoterol. Not available in ...
Botox Cosmetic (Popularity: ): Producer of Botulinum Toxin type A, offers information on treatment and answers to common questions, a searchable list of physicians, ...
|
|
Popular Sites |
|
Botox Cosmetic (Popularity: ): Producer of Botulinum Toxin type A, offers information on treatment and answers to common questions, a searchable list of physicians, ...
Luxiq (Popularity: ): A foam-based topical medication for treating various dermatological conditions. Includes separate physician and patient areas, prescribing information, patient materials, application ...
Avonex (Popularity: ): Interferon beta-1a. Details about this Multiple Sclerosis prescription drug treatment. Research and information on symptoms and diagnosis. Includes FAQs and ...
Symbicort - AstraZeneca International (Popularity: ): An asthma treatment consisting of the inhaled corticosteroid budesonide together with the rapid- and long-acting ß2-agonist formoterol. Not available in ...
Rebif (Popularity: ): An interferon beta 1-a for relapsing forms of MS. Find out about recommended dose, potential side effects, clinical studies and ...
|
|
Related Press |
|
CVS Caremark Announces Plan To Remove Walgreens From PBM Pharmacy Network and Transition Pharmacy Care To Participating Providers (Popularity: ): CVS Caremark Corporation (NYSE: CVS) today announced that, while it has worked diligently to come to terms with Walgreens on ...
Great Lakes Pharmaceuticals, Inc., Announces $2.4 Million Equity Financing (Popularity: ): Great Lakes Pharmaceuticals, Inc. announced today the completion of Series A $2.4 million equity financing led by Ohio investment funds ...
Symbollon Pharmaceuticals, Inc. Evaluates the Clinical Effects of IoGen(TM) on Fibrocystic Breast Disease (Popularity: ): Iodine has been used as an antimicrobial for the last century. Much has been written about molecular iodine yet many ...
Watson' Launches Generic Kadian(R) (Popularity: ): PARSIPPANY, N.J., Nov. 10, 2011 -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that it has received approval from the ...
Cerimon Pharmaceuticals Initiates Phase II Study to Evaluate Simulect(R) (Basiliximab) for Noninfectious Uveitis (Popularity: ): Cerimon Pharmaceuticals, Inc., announced today it has initiated a Phase II proof-of-concept study of Simulect(R) (basiliximab) for the treatment of ...
|
|
Related Articles |
|
|
|